Pharma Firms Want Protection From FDA Actions When Listing On ClinicalTrials.Gov
Executive Summary
Pharmaceutical manufacturers are seeking assurances from FDA that information about clinical studies posted on clinicaltrials.gov will not expose them to charges of promoting products for unapproved uses
You may also be interested in...
Allergan Freedom From Expression Suit Challenges REMS, Off-Label Powers
Allergan's suit against FDA seeking a court ruling that it can provide physicians with information on unapproved uses of Botox is another milestone in the debate over off-label promotion, but it also may be the first legal indication of the power of Risk Evaluation and Mitigation Strategies to impact sales
Allergan Freedom From Expression Suit Challenges REMS, Off-Label Powers
Allergan's suit against FDA seeking a court ruling that it can provide physicians with information on unapproved uses of Botox is another milestone in the debate over off-label promotion, but it also may be the first legal indication of the power of Risk Evaluation and Mitigation Strategies to impact sales
Allergan's Freedom From Expression Suit Challenges Gov't REMS, Off-Label Powers
The firm wants to go beyond the REMS requirements and offer treatment guidance, not just risk information, about the use of Botox for spasticity, an unapproved condition.